



# MARKET RELEASE

5 September 2014

**Prana Biotechnology Limited**

**TRADING HALT**

The securities of Prana Biotechnology Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 9 September 2014 or when the announcement is released to the market.

Security Code:           PBT

Kobe Li  
**Senior Adviser, Listings Compliance (Melbourne)**

Friday 5<sup>th</sup> September 2014

Kobe Li  
ASX Compliance Pty Limited  
Level 4, North Tower  
525 Collins Street  
Melbourne VIC 3000

Dear Mr Kobe Li,

**Request for Trading Halt for Prana Biotechnology Limited**

In accordance with ASX Listing Rule 17.1, the Directors of Prana Biotechnology Limited ("the Company") request an immediate trading halt in respect of its securities (ASX Code: PBT).

In requesting the trading halt, the Company provides the following information:

- The trading halt is necessary as the Company is preparing an announcement for the market in relation to the approval of Orphan Drug Designation for PBT2;
- Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until the announcement is made to the market, not later than Monday, 8<sup>th</sup> September 2014, 10:00am; and
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely,



Geoffrey Kempler  
Executive Chairman and CEO